What is NAGE's pharmaceuticals segment — operating expenses?

NAGE (NAGE) reported pharmaceuticals segment — operating expenses of $468K in Q1 2026.

How has NAGE's pharmaceuticals segment — operating expenses changed year-over-year?

NAGE's pharmaceuticals segment — operating expenses increased by 27.2% year-over-year, from $368K to $468K.

What does pharmaceuticals segment — operating expenses mean?

The aggregate of all costs incurred to operate the pharmaceutical segment, excluding the cost of sales. This includes research and development, marketing, advertising, and administrative overhead. It provides a comprehensive view of the segment's operational cost structure and burn rate.

NAGE NAGE Pharmaceuticals segment — Operating Expenses

Other segment segments

Consumer Products segment

$10.17M+18.6%

Ingredients segment

$470K+47.3%

Analytical Reference Standards and Services segment

$44K-58.9%

Similar metrics at other companies

BAXPharmaceuticals — Selling, general and administrative expenses

$102M-1.0%

VAN

VANIBiopharm Division — Operating Expenses

$6M0.0%

BLCOPharmaceuticals — Selling, general and administrative (Note 4)

$138M-9.8%

ANABBiopharma Company — Operating Expenses

$52.81M+3.0%

BAXPharmaceuticals — Cost of Sales

$458M+15.7%

CAHPharmaceutical and Specialty Solutions — Total Costs & Expenses

$55.33B+11.2%

Other financials

Income statement

See full

Revenue$31.5M+3.3%

Gross profit$20.0M+3.3%

Operating income$1.6M-67.0%

Net income$6.3M+24.8%

EPS (diluted)$0.07+16.7%

Balance sheet

See full

Cash & equivalents$66.5M+19.7%

Total debt$2.6M-26.9%

Total equity$82.3M+48.8%

Total assets$114.3M+40.6%

Cash flow

See full

Operating cash flow-$1.2M-115%

Valuation

See full

Market cap$254.07M-74.9%

Enterprise value$190.09M-79.7%

P/E13.6×-43.5×

P/S2×-6.8×

Profitability

See full

Gross margin64.3%+1.8pp

Operating margin10%-2.2pp

Net margin14.3%+1.2pp

FCF margin-70.4%—

Returns & leverage

See full

Return on equity27.1%-6.4pp

Debt / equity0×0.0×

Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: NAGE’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's pharmaceuticals segment — operating expenses.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NAGE's pharmaceuticals segment — operating expenses?: NAGE (NAGE) reported pharmaceuticals segment — operating expenses of $468K in Q1 2026.
How has NAGE's pharmaceuticals segment — operating expenses changed year-over-year?: NAGE's pharmaceuticals segment — operating expenses increased by 27.2% year-over-year, from $368K to $468K.
What does pharmaceuticals segment — operating expenses mean?: The aggregate of all costs incurred to operate the pharmaceutical segment, excluding the cost of sales. This includes research and development, marketing, advertising, and administrative overhead. It provides a comprehensive view of the segment's operational cost structure and burn rate.